Related Experiment Video
Updated: Aug 2, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022
Paolo A Ascierto1, Christian Blank2, Alexander M Eggermont3,4
1Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy. paolo.ascierto@gmail.com.
Experts debated key melanoma management strategies, including anti-lymphocyte-activation gene (LAG)-3 vs. ipilimumab with anti-programmed death (PD)-1 therapy and the role of adjuvant treatments. Audience votes reflected the dynamic discussions on these critical topics.
Area of Science:
- Oncology
- Immunotherapy
- Surgical Oncology
Background:
- The 2022 Melanoma Bridge congress hosted a Great Debate session.
- Leading experts presented counterpoint views on contemporary melanoma management challenges.
Purpose of the Study:
- To explore and debate pivotal issues in melanoma treatment.
- To gauge expert and audience perspectives on controversial topics in melanoma care.
Main Methods:
- Five key debate topics were addressed by invited speakers.
- Expert opinions were presented on specific treatment choices and strategies.
- Audience voting was conducted before and after each debate to assess opinion shifts.
Main Results:
- Debates covered anti-lymphocyte-activation gene (LAG)-3 therapy versus ipilimumab in combination with anti-programmed death (PD)-1 therapy.
- Discussions addressed the acceptability of anti-PD-1 monotherapy as a clinical trial comparator.
- The utility of adjuvant treatment and its specific role in stage II melanoma were debated.
- The evolving role of surgery in melanoma management was also a key discussion point.
Conclusions:
- The debates highlighted ongoing controversies and evolving expert opinions in melanoma management.
- Audience engagement through voting underscored the dynamic nature of these clinical discussions.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Prevention
Some...
Tumor Immunotherapy
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

